Additionally, in the treatment of neuroblastoma, anlotinib was found to improve the efficacy of anti-PD-1 mAbs by promoting vascular normalization via CD4+ T cells and by improving the immunosuppressive microenvironment within the tumor [58]. The gene discussed is PDCD1; the disease is neoplasm.